Sirolimus News and Research

RSS

Drug-drug or drug-food interactions may offer opportunities to lower costs

Exploiting interactions between food and drugs could dramatically lower the rapidly rising costs of several anticancer drugs, and perhaps many other medications, two cancer-pharmacology specialists suggest in a commentary in the July 16, 2007, issue of the Journal of Clinical Oncology.

17 Jul 2007

Key findings on new-generation stent

New data reported at the 30th Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions (SCAI), offered clues to the fate of a new-generation drug-eluting stent that is vying for a place in the treatment of coronary artery disease.

11 May 2007

Heart transplant patients benefit from new approach to immunosuppression

A new immunosuppression regimen for heart transplant patients can improve kidney function and prevent transplant coronary artery disease, according to two new Mayo Clinic studies.

27 Apr 2007

Micell Technologies presents data on novel drug-eluting stents

Micell Technologies has announced that the Company will be presenting data on use of its supercritical fluid (SCF) surface modification technology for drug-eluting stents at the upcoming Society for Biomaterials 2007 Annual Meeting, April 19-21 2007 in Chicago, Illinois.

19 Apr 2007

Long-term safety of drug-eluting stents in off-label use

Research presented at the American College of Cardiology's Innovation in Intervention: i2 Summit 2007 in New Orleans, La, paints a picture of the "real world" use of drug-eluting stents and offers new insight into the connection between blood clotting, or thrombosis, in the stent - a dangerous complication - and adherence and responsiveness to anti-clotting medication.

3 Apr 2007

Ultrasound targets angioplasty

World Congress of Cardiology 2006 - A simple technique - combining cardiac ultrasound with a heart muscle-stimulating drug - can identify the MI patients who would benefit most from angioplasty after thrombolysis, reports a study in Hot Line session II.

6 Sep 2006

First drug-eluting stent approved in Europe for most severe form of arterial disease in the leg

Cordis Endovascular, a division of Cordis Corporation, announced today that the Cypher Select Sirolimus-eluting stent received CE (Communite European) Mark in Europe for use in the treatment of severe claudication and critical limb ischemia (CLI) of infrapopliteal lesions, which is the most severe form of arterial disease in the leg.

6 Sep 2006

Rapamycin (sirolimus) may be effective in treating kidney disease

A widely available drug may be effective in treating kidney disease, report scientists at the University of California, Santa Barbara. They describe the discovery in the online edition of the Proceedings of the National Academies of Science.

21 Mar 2006

Sirolimus-releasing stents more effective than vascular brachytherapy for treating restenosis within a stent

David R. Holmes, Jr., M.D., of Mayo Clinic, Rochester, Minn., and colleagues with the SISR trial compared the use of vascular brachytherapy (VBT - intra-coronary radiation therapy) with implantation of the sirolimus-eluting stent for the treatment of restenosis occurring within a previously placed bare-metal stent

13 Mar 2006

Researchers transplant insulin-producing neonatal porcine islet cells into monkeys

A team of researchers from the University of Alberta, the Yerkes National Primate Research Center of Emory University and the Emory Transplant Center has successfully transplanted insulin-producing neonatal porcine islet cells into monkeys, a procedure the researchers say represents a promising intermediate solution to the critical supply problem in clinical islet cell transplantation.

27 Feb 2006

Coronary stents that release the drugs sirolimus or paclitaxel produce similar results

Use of coronary stents that release the drugs sirolimus or paclitaxel produced similar results in patients with new coronary artery lesions, according to a study in JAMA: The Journal of the American Medical Association.

24 Feb 2006

Sirolimus reduces risk of cancer in kidney transplant patients

A new study published in this month's issue of the Journal of the American Society of Nephrology shows that the risk of cancer in kidney transplant recipients was reduced by more than 50% at five years post transplantation in those patients who were treated with sirolimus following withdrawal of cyclosporine at three months.

13 Feb 2006

Study finds benefits, less organ rejection using immunosuppressive combination for heart transplants

A new study led by researchers at the UCLA Heart Transplant Program showed that one particular combination using tacrolimus (TAC or PrografÒ also known as FK506) had significant anti-rejection benefits for heart transplant patients over other combinations.

22 May 2005

New trend in treating heart disease in diabetics - angioplasty using the Cypher Sirolimus-eluting coronary stent

The World Health Organisation has predicted an increase in the worldwide prevalence of diabetes of epidemic proportions . Eighty percent of people with diabetes will die from cardiovascular complications -- stroke and/or coronary heart disease (CHD).

12 May 2005

Coronary artery stents that release medication appear more effective than traditional stents for patients with heart attack

A type of coronary artery stent that releases a medication appears to result in better outcomes than traditional stents for heart attack patients, according to a study in the May 4 issue of JAMA.

3 May 2005

Drug eluting stents as effective as vascular brachytherapy in preventing restenosis

After angioplasty is performed to widen clogged arteries, surgeons frequently use tiny wire-mesh tubes called stents to keep blood vessels open. But despite stenting, scar tissue can form to create new blockages -- a process called in-stent restenosis (ISR).

7 Mar 2005

Sirolimus drug-coated stent causes less inflammation than bare metal stents

In the treatment of coronary artery disease, a sirolimus drug-coated stent causes less inflammation than bare metal stents, according to preliminary research presented at the American Heart Association annual meeting by Loyola University Health System, Maywood, Ill.

11 Nov 2004

Early reports of thrombosis after insertion of drug-eluting stent

Authors of a research letter in this week’s issue of THE LANCET highlight how the use of drug-eluting stents (DES) may carry a risk of subsequent thrombosis if stenting is accompanied by a withdrawal of antiplatelet therapy.

21 Oct 2004

Drug-eluting stents (DES), increasingly used in coronary angioplasty, have benefits over bare-metal stents

A pooled analysis of 11 previously published trials provides evidence that drug-eluting stents (DES)—increasingly used in coronary angioplasty—have benefits over bare-metal stents (BMS) by reducing the need for later revascularisation and reducing the risk of cardiac events

15 Aug 2004

Sirolimus-based therapy following early cyclosporine withdrawal improves transplanted kidney structure and function

Kidney histology and function three years after transplantation are better in kidney-transplant patients who remain on sirolimus-based therapy following early withdrawal of cyclosporine than in patients who continue on this calcineurin inhibitor, according to a new study published in the American Journal of Transplantation.

11 Jun 2004